Serafim  Papadimitriou

Yun Dai

Associate Professor

biography

Yun Dai, MD/PhD, Associate Professor, Division of Hematology/Oncology, Massey Cancer Center, Virginia Commonwealth University. His research has been funded by NCI/NIH as RO1, R21, Multiple Myeloma SPORE, and Lymphoma SPORE, and by various foundations/societies. He has served on review panels of the NIH/NCI and the Israeli-French High Council for Scientific & Technological Research. He has extensively served on journal editorial boards and as a peer reviewer of numerous journals particularly in cancer research, including PNAS, Cancer Res, Blood, Oncogene, etc. He is active members of AACR and ASH, and serves on the Executive Committee of US Chinese Anti-Cancer Society (USCACA) and as Chair of the 7th USCACA Annual Meeting at AACR 2015. He has published 67 original research papers and 10 reviews in high-impact journals, and 7 book chapters.

 

Area of Interest

Dr. Dai’s research interest and expertise are focused on cancer biology and precision targeted therapy, especially in hematologic malignancies.


top publication

1. Harvey S, Decker R, Dai Y, Schaefer G, Tang L, Kramer L, Dent P, Grant S. Interactions between 2-fluoroadenine 9--D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells. Clin Cancer Res 7(2):320-330, 2001. (IF: 7.74)
2. Decker RH, Dai Y, Grant S. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ 8(7):715-724, 2001. (IF: 8.85)
3. Dai Y, Yu J, Singh V, Tang L, Wang Z, McInistry R, Dent P, Grant S. Pharmacologic inhibitors of the MEK/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 61(13):5106-5115, 2001. (IF: 8.30)
4. Rahmani M, Dai Y, Grant S. The Histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a TNF-mediated process. Exp Cell Res 277(1):31-47, 2002. (IF: 4.71)
5. Wang Z, Wang S, Dai Y, Grant S. Bryostatin 1 increases 1--D-arabinofuranosylcytosine-induced cytochrome c release and apoptosis in human leukemia cells ectopically expressing Bcl-XL. J Pharmacol Exp Ther 301(2):568-577, 2002. (IF: 3.99)
6. Cartee L, Smith R, Dai Y, Rahmani M, Rosata A, Almenara J, Dent P, Grant S. Synergistic induction of apoptosis in human myeloid leukemia cells (U937 and HL-60) by PMA and flavopiridol proceeds via activation of both the intrinsic and TNF-mediated extrinsic cell death pathway. Mol Pharmacol 61(6):1313-1321, 2002. (IF: 5.48)
7. Dai Y, Dent P, Grant S. Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514A. Cell Cycle 1(2):143-152, 2002. (IF: 5.36)
8. McKinstry R., Qiao L., Yacoub A, Dai Y, et al. Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells. Cancer Biol Ther 1(3):243-253, 2002. (IF: 2.64)
9. Decker RH, Wang S, Dai Y, Dent P and Grant S. Loss of Bcl-2 phorsphorylation loop domain is required to protect human myoloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis. Cancer Biol Ther 1(2):136-144, 2002. (IF: 2.64)
10. Dai Y, Landowoski HT, Rosen TS, Dent P, Grant S. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and –resistant myeloma cells through an IL-6-independent mechanism. Blood 100(9):3333-3343, 2002. (IF: 9.90)
11. Yu C, Dai Y, Dent P, Grant S. Coadministration of UCN-01 with MEK1/2inhibitors potently induces apoptosis in Bcr/Abl(+) leukemia cells sensitive and resistant to STI571. Cancer Biol Ther 1(6):674-682, 2002. (IF: 2.64)
12. Decker RH, Levin J, Kramer L, Dai Y and Grant S. Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1-[-D-arainofuranosyl]-cytosine (ara-C)-induced apoptosis. Biochem Pharmacol 65(12):1997-2008, 2003. (IF: 4.70)
13. Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P, Grant S. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res 63(8):1822-1833, 2003. (IF: 8.65)
14. Rosato RR, Almenara JA, Dai Y, Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2(12):1273-1284, 2003. (IF: 5.23)
15. Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, Grant S. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 63(23):8420-8427, 2003. (IF: 8.65)